Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Return on Sales (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Return on Sales readings, the most recent being 0.29% for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales fell 94.0% year-over-year to 0.29%, compared with a TTM value of 0.02% through Dec 2025, up 5.0%, and an annual FY2025 reading of 0.02%, up 5.0% over the prior year.
  • Return on Sales hit 0.29% in Q4 2025 for Apellis Pharmaceuticals, down from 0.47% in the prior quarter.
  • The five-year high for Return on Sales was 4.7% in Q4 2021, with the low at 351.83% in Q2 2021.
  • Median Return on Sales over the past 5 years was 0.91% (2023), compared with a mean of 21.11%.
  • The sharpest move saw Return on Sales crashed -2691bps in 2021, then skyrocketed 34228bps in 2022.
  • Year by year, Return on Sales stood at 4.7% in 2021, then tumbled by -178bps to 3.67% in 2022, then surged by 93bps to 0.27% in 2023, then skyrocketed by 337bps to 0.65% in 2024, then plummeted by -146bps to 0.29% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 0.29%, 0.47%, and 0.24% for Q4 2025, Q3 2025, and Q2 2025 respectively.